Skip to main content

Vyant Bio, Inc.

VYNTDelisted May 4, 2023
Industry
Services-Medical Laboratories
SEC CIK
0001349929

Vyant Bio, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 17 institutions reported holding it in 13F filings for Q1 2023, worth $136.8K in total; no superinvestor held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 12:52 PM ET

Revenue flow, FY2022

Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2022: $22.7M (3406.9% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Vyant Bio, Inc., annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endDec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Filing10-K10-K10-K10-K10-K
Reported–Mar 1, 2022–Feb 20, 2020Jan 16, 2019
Revenue$666.0K$1.15M$5.75M$7.30M$27.5M
Cost of revenue––$3.35M$3.70M$18.7M
Gross profit––$2.40M$3.60M$8.75M
Operating expenses$16.6M$16.9M$10.6M$9.31M$30.7M
Research and development$6.77M$4.27M–$0$2.49M
Selling, general and administrative––$6.59M$5.17M$19.2M
Operating income-$15.9M-$15.7M-$8.18M-$5.70M-$22.0M
Interest expense––$272.0K$1.44M$2.12M
Income tax––$0-$512.0K$0
Net income-$22.7M-$40.9M-$8.00M-$6.71M-$20.4M
EPS, basic$-3.87––––
Weighted shares, basic5.87M––––
Weighted shares, diluted5.87M––––
Margins and growth
Gross margin––41.7%49.3%31.8%
Operating margin-2389.2%-1368.1%-142.3%-78.1%-80.0%
Net margin-3406.9%-3559.1%-139.1%-91.8%-74.2%
Revenue growth, year over year−42.0%−80.0%−21.3%−73.4%−5.7%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Vyant Bio, Inc., annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endDec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Filing10-K10-K10-K10-K10-K
Reported–Mar 1, 2022–Feb 20, 2020Jan 16, 2019
Cash and equivalents$10.0M$20.6M$2.44M$3.88M$161.0K
Accounts receivable$323.0K$434.0K$779.0K$696.0K$7.04M
Inventory$53.0K$475.0K––$144.0K
Total current assets$11.5M$23.2M$4.11M$7.18M$9.35M
Property, plant and equipment$1.11M$1.02M–$558.0K$4.06M
Goodwill–$2.16M$2.98M$3.09M$17.3M
Intangible assets$0$8.79M$0$2.90M$4.00M
Total assets$15.2M$37.6M$8.35M$14.9M$35.4M
Accounts payable$655.0K$740.0K–––
Total current liabilities$3.67M$5.43M$4.26M$6.97M$27.3M
Long-term debt$57.0K$57.0K–––
Total liabilities$5.30M$6.35M$4.37M$7.52M$28.6M
Shareholders' equity$9.91M$31.3M$3.98M$7.38M$6.80M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Vyant Bio, Inc., annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endDec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Filing10-K10-K10-K10-K10-K
Reported–Mar 1, 2022–Feb 20, 2020Jan 16, 2019
Operating cash flow-$13.7M-$17.0M-$5.37M-$8.66M-$12.6M
Capital expenditures$617.0K$535.0K$39.0K$28.0K$649.0K
Free cash flow-$14.3M-$17.5M-$5.41M-$8.69M-$13.2M
Depreciation and amortization$522.0K$550.0K–––
Stock-based compensation$1.19M$1.00M$179.0K$263.0K$921.0K
Investing cash flow$3.26M$29.6M$1.01M$9.09M$1.08M
Financing cash flow-$149.0K$7.19M$2.64M$3.31M$2.15M
Net change in cash-$10.6M$19.8M-$1.79M$3.72M-$9.38M
Ratio
Stock-based compensation, % of revenue178.1%87.4%3.1%3.6%3.4%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Vyant Bio, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Mar 15, 20236.27M−78.4%SEC
Nov 10, 20225.91M−79.6%SEC
Aug 18, 202229.3M+1.2%SEC
May 10, 202229.4M+1.5%SEC
Mar 15, 202229.0M+163.4%SEC
Nov 9, 202129.0M+611.4%SEC
Aug 12, 202129.0M+1,156.1%SEC
May 10, 202129.0M+1,275.3%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.